Emergent BioSolutions | EBS - Assets


Emergent BioSolutions reported $1.82B in Assets for its fiscal quarter ending in December of 2023.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Akebia Therapeutics USD 362.52M 14.04M Mar/2026
ALKERMES USD 4.26B 1.77B Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amarin USD 645.76M 25.01M Mar/2026
ANI Pharmaceuticals USD 1.42B 18.41M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Exelixis USD 2.59B 250.83M Mar/2026
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Lonza CHF 18.97B 164M Dec/2025
Merck USD 128.68B 8.18B Mar/2026
Moderna USD 11.49B 850M Mar/2026
Myriad Genetics USD 673.7M 32.9M Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Pacira USD 1.21B 56.38M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Xoma USD 263.15M 39.7M Sep/2025